Skip to main content
Premium Trial:

Request an Annual Quote

PROOF, IO Informatics to Develop App Aimed at Heart, Lung, and Kidney Disease

NEW YORK (GenomeWeb News) – The Centre of Excellence for the Prevention of Organ Failure, or PROOF Centre, and IO Informatics today announced a deal to develop a web-based software application addressing chronic heart, lung, and kidney disease.

The application will be developed so that clinicians can use it on handheld device and other technology, and it will be used with blood tests developed by the PROOF Centre that target chronic disease and transplantation.

According to the center and IO Informatics, the application will give an overall score indicating patient risk level and associated clinical recommendations to help guide decision making. The scores and recommendations will be based on gene expression data, protein expression data, and longitudinal clinical observations.

Erich Gombocz, vice president and chief science officer of Berkeley, Calif.-based Ion Informatics, said in a statement that future applications of the technology will allow for automated, pre-symptomatic screening for almost any biomarker-based risk event, disease severity characterization, and treatments that are patient-centric.

Financial and other terms of the deal were not disclosed.